Cellectis

AGM Information • Oct 8, 2014

Individual Shareholder Meeting

On October 23, 2014 at Cellectis' headquarters in Paris

Event Details:

Date: October 23, 2014 Time: 6:00 to 8:30PM Location: Cellectis – 11 rue Watt – 75013 Paris

André Choulika, PhD, Chairman and Chief Executive Officer of Cellectis, Mathieu Simon, MD, Executive Vice President and Thierry Moulin, Chief Financial Officer, will present to the Company's individual shareholders perspectives on developing immunotherapies based on engineering CART allogeneic (UCART) lymphocytes.

Agenda:

Reception from 5:45PM

• Presentation of Cellectis and Cellectis plant sciences André Choulika
• The Company's therapeutic programs Mathieu Simon
• First-Half 2014 Financial Results Thierry Moulin
• Q&A
• Cocktail dinner

Feel free to send your questions ahead of the meeting at media@cellectis.com.

Please RSVP with:

Cellectis / Jennifer Moore jennifer.moore@cellectis.com Phone: 01 81 69 16 00

Upon invitation – Still time to register

About Cellectis

Cellectis is a biopharmaceutical company focused on oncology. The company's mission is to develop a novel generation of therapy based on engineered T-cells to treat cancer. Cellectis capitalizes on its 14 years of expertise in genome engineering, based on TALEN™, meganucleases and the state-of-the-art electroporation technology PulseAgile, to create a new generation of cancer immunotherapy for treating leukemias and solid tumors. Cellectis adoptive cancer immunotherapy for chronic and acute leukemias is based on allogeneic T-cell chimeric antigen receptor (CAR) technology. CAR technologies are designed to target surface antigens expressed on cells. The Cellectis Group is focused on life sciences and uses leading genome engineering technologies to build innovative products in various fields and markets. Cellectis is listed on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com.